DealsJun 25, 2026, 04:37 PM
Aytu BioPharma Terminates Metadate CD License Agreement with Lannett
AI Summary
Aytu BioPharma, Inc. and Lannett Company, Inc. mutually agreed to terminate their exclusive license agreement for Metadate CD®, effective June 23, 2026. The agreement, originally signed in May 2022, allowed Aytu BioPharma to sell and distribute Metadate CD®. For the quarter ended March 31, 2026, Metadate CD® generated net revenue of $49,000. Aytu BioPharma retains the right to sell existing inventory and will continue to provide royalty reports and payments until sales cease.
Key Highlights
- Aytu BioPharma and Lannett mutually agreed to terminate the Metadate Agreement.
- The exclusive license agreement for Metadate CD® was terminated effective June 23, 2026.
- The original agreement was entered into on May 11, 2022, and amended on July 6, 2023, and July 17, 2025.
- Aytu BioPharma may continue to sell existing Metadate CD® inventory and pay royalties.
- Net revenue from Metadate CD® was $49,000 for the quarter ended March 31, 2026.
Price Impact
More from AYTU